Simcha Therapeutics, a New Haven, Conn.-based biotechnology company developing biologic drugs that modulate cytokine pathways, launched with $25m in Series A financing.
Investors included WuXi AppTec’s Corporate Venture Fund, Sequoia Capital China and Connecticut Innovations.
The company intends to use the funds to advance its development efforts.
Simcha’s lead program involves a customized variant of interleukin-18 (IL-18), a cytokine with potent antitumor effects, developed in the lab of Scientific Founder Aaron Ring, M.D., Ph.D., Assistant Professor of Immunobiology at the Yale School of Medicine.
The company uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system. The lead asset, ST-067, activates the IL-18 receptor, triggering potent inflammatory signaling in antitumor immune cells of both the adaptive and innate branches of the immune system. Simcha plans to build out a full executive team as the company prepares to move ST-067 into the clinic next year.